|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2015070061A1
(en)
*
|
2013-11-07 |
2015-05-14 |
Memorial Sloan-Kettering Cancer Center |
Anti-wt1/hla bi-specific antibody
|
|
US10239952B2
(en)
*
|
2011-04-01 |
2019-03-26 |
Memorial Sloan Kettering Cancer Center |
Anti-WT1/HLA bi-specific antibody
|
|
EA201391449A1
(ru)
|
2011-04-01 |
2014-03-31 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Антитела против пептидов цитозоля
|
|
WO2014100615A1
(en)
|
2012-12-20 |
2014-06-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
CN111139256A
(zh)
|
2013-02-20 |
2020-05-12 |
诺华股份有限公司 |
使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
US20140271644A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Combination/adjuvant therapy for wt-1-positive disease
|
|
WO2014143835A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Combination/adjuvant therapy for wt-1-positive disease
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CN106170297A
(zh)
*
|
2013-09-20 |
2016-11-30 |
纪念斯隆-凯特琳癌症中心 |
用于wt‑1‑阳性疾病的组合/辅助疗法
|
|
SG11201602249RA
(en)
|
2013-10-18 |
2016-05-30 |
Deutsches Krebsforsch |
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
|
|
CA2934033A1
(en)
*
|
2013-11-07 |
2015-05-14 |
Memorial Sloan-Kettering Cancer Center |
Fc-enhanced anti-wt1/hla antibody
|
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP4420663A3
(en)
|
2013-12-20 |
2024-10-30 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
|
US20160152725A1
(en)
*
|
2014-02-25 |
2016-06-02 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
US11390921B2
(en)
|
2014-04-01 |
2022-07-19 |
Adaptive Biotechnologies Corporation |
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
|
|
LT3129470T
(lt)
|
2014-04-07 |
2021-07-12 |
Novartis Ag |
Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
|
|
MX2017000646A
(es)
*
|
2014-07-15 |
2017-04-27 |
Juno Therapeutics Inc |
Celulas geneticamente modificadas para terapia celular adoptiva.
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
CN107109420A
(zh)
|
2014-07-21 |
2017-08-29 |
诺华股份有限公司 |
使用cll-1嵌合抗原受体的癌症治疗
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗bcmaキメラ抗原受容体を使用した癌の処置
|
|
AU2015305531B2
(en)
|
2014-08-19 |
2021-05-20 |
Novartis Ag |
Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
|
|
EP3191592A1
(en)
|
2014-09-11 |
2017-07-19 |
Novartis AG |
Inhibition of prmt5 to treat mtap-deficiency-related diseases
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
CN114107424A
(zh)
|
2014-10-08 |
2022-03-01 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
DK3220926T3
(da)
|
2014-11-17 |
2025-03-24 |
Adicet Therapeutics Inc |
Konstruerede gamma-delta-t-celler
|
|
WO2016089883A1
(en)
|
2014-12-01 |
2016-06-09 |
Novartis Ag |
Compositions and methods for diagnosis and treatment of prostate cancer
|
|
JP6699013B2
(ja)
*
|
2014-12-25 |
2020-05-27 |
国立大学法人三重大学 |
Wt1由来ペプチド認識抗体
|
|
CA2972597A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016154047A2
(en)
*
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
|
HK1249048A1
(zh)
*
|
2015-04-03 |
2018-10-26 |
Eureka Therapeutics, Inc. |
靶向afp肽/mhc复合体的构建体及其用途
|
|
HRP20220893T1
(hr)
|
2015-04-08 |
2022-10-14 |
Novartis Ag |
Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
|
|
EP3283619B1
(en)
|
2015-04-17 |
2023-04-05 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN106188274A
(zh)
*
|
2015-05-06 |
2016-12-07 |
广州市香雪制药股份有限公司 |
识别rhamm抗原短肽的t细胞受体
|
|
NL2014935B1
(en)
|
2015-06-08 |
2017-02-03 |
Applied Immune Tech Ltd |
T cell receptor like antibodies having fine specificity.
|
|
EP3307319A4
(en)
*
|
2015-06-09 |
2019-05-22 |
Memorial Sloan Kettering Cancer Center |
T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
FR3039832A1
(fr)
*
|
2015-08-04 |
2017-02-10 |
Univ Francois Rabelais De Tours |
Igg1 et leur utilisation therapeutique
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
CN107949573B
(zh)
|
2015-09-01 |
2022-05-03 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
EP3359565A1
(en)
*
|
2015-10-09 |
2018-08-15 |
Immatics Biotechnologies GmbH |
Anti-wt1/hla-specific antibodies
|
|
IL295398B2
(en)
*
|
2015-10-23 |
2025-01-01 |
Eureka Therapeutics Inc |
Antibody/T-cell receptor chimeric constructs and their uses
|
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
|
EP3380620B1
(en)
|
2015-11-23 |
2024-07-03 |
Novartis AG |
Optimized lentiviral transfer vectors and uses thereof
|
|
CN116121281A
(zh)
*
|
2015-11-27 |
2023-05-16 |
卡瑟里克斯私人有限公司 |
经遗传修饰的细胞及其用途
|
|
MX2018006789A
(es)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Receptores quimericos modificados y composiciones y metodos relacionados.
|
|
EP3383419B1
(en)
|
2015-12-03 |
2022-08-03 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
|
AU2016362129A1
(en)
|
2015-12-04 |
2018-06-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
SG11201805451TA
(en)
|
2015-12-30 |
2018-07-30 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
CA3010224A1
(en)
|
2016-01-22 |
2017-07-27 |
Merck Sharp & Dohme Corp. |
Anti-coagulation factor xi antibodies
|
|
GB201604492D0
(en)
*
|
2016-03-16 |
2016-04-27 |
Immatics Biotechnologies Gmbh |
Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
CA3018253A1
(en)
|
2016-03-31 |
2017-10-05 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
US12144850B2
(en)
|
2016-04-08 |
2024-11-19 |
Purdue Research Foundation |
Methods and compositions for car T cell therapy
|
|
US10233255B2
(en)
|
2016-04-25 |
2019-03-19 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind STAT3
|
|
WO2017197347A1
(en)
|
2016-05-12 |
2017-11-16 |
Adicet Bio, Inc. |
METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
|
|
TWI895621B
(zh)
|
2016-05-27 |
2025-09-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
EA201892716A1
(ru)
|
2016-06-14 |
2019-05-31 |
Мерк Шарп И Доум Корп. |
Антитела к фактору свертывания xi
|
|
EP3475446A1
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
|
WO2018005775A1
(en)
|
2016-06-29 |
2018-01-04 |
Memorial Sloan-Kettering Cancer Center |
Cd47 blockade enhances therapeutic activity of antibodies to low density cancer epitopes
|
|
US12304935B2
(en)
|
2016-07-29 |
2025-05-20 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
|
AU2017341047B2
(en)
|
2016-10-07 |
2024-10-10 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
KR102576042B1
(ko)
|
2016-10-11 |
2023-09-07 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
AU2017366739B2
(en)
|
2016-12-02 |
2023-11-23 |
Angeles Therapeutics, Inc. |
Synthetic immune receptors and methods of use thereof
|
|
ES2961666T3
(es)
|
2016-12-03 |
2024-03-13 |
Juno Therapeutics Inc |
Métodos para determinar la dosificación de células CAR-T
|
|
JP2019536460A
(ja)
|
2016-12-03 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
Car−t細胞の調節方法
|
|
WO2018106732A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
KR102630036B1
(ko)
|
2016-12-23 |
2024-01-29 |
마크로제닉스, 인크. |
Adam9-결합 분자, 및 이것의 사용 방법
|
|
CN107698681B
(zh)
*
|
2016-12-28 |
2020-07-07 |
天津天锐生物科技有限公司 |
一种识别hla-a2/rmfpnapyl的单域抗体
|
|
JP7429338B2
(ja)
|
2017-01-10 |
2024-02-08 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法および関連方法のエピジェネティック解析
|
|
MX2019008538A
(es)
|
2017-01-20 |
2019-11-05 |
Juno Therapeutics Gmbh |
Conjugados de superficie celular y composiciones y métodos celulares relacionados.
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラt細胞受容体タンパク質を用いた癌の治療
|
|
CA3051481A1
(en)
|
2017-02-07 |
2018-08-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
|
AU2018224856B2
(en)
|
2017-02-27 |
2025-04-03 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
SG11201907434RA
(en)
|
2017-03-22 |
2019-10-30 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
JP7284707B2
(ja)
|
2017-04-07 |
2023-05-31 |
ジュノー セラピューティクス インコーポレイテッド |
前立腺特異的膜抗原(psma)またはその改変型を発現する操作された細胞および関連方法
|
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
|
MA54103A
(fr)
|
2017-04-14 |
2021-09-15 |
Juno Therapeutics Inc |
Procédés d'évaluation de la glycosylation de surface cellulaire
|
|
CN110741016A
(zh)
|
2017-04-26 |
2020-01-31 |
优瑞科生物技术公司 |
嵌合抗体/t-细胞受体构筑体及其用途
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
KR102412805B1
(ko)
*
|
2017-05-31 |
2022-06-27 |
크라제 메디컬 씨오 리미티드 |
세포 면역 요법을 위한 조성물 및 방법
|
|
US11740231B2
(en)
|
2017-06-02 |
2023-08-29 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
|
WO2018231958A1
(en)
*
|
2017-06-13 |
2018-12-20 |
Adaptive Biotechnologies Corp. |
Determining wt-1 specific t cells and wt-1 specific t cell receptors (tcrs)
|
|
CN111032076A
(zh)
|
2017-06-14 |
2020-04-17 |
阿迪塞特生物公司 |
能够以hla限制性方式结合hla-a2/tyrd的抗体及其用途
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
PL3538645T3
(pl)
|
2017-06-20 |
2021-11-08 |
Institut Curie |
Komórki odpornościowe z defektem suv39h1
|
|
US11530413B2
(en)
|
2017-07-21 |
2022-12-20 |
Novartis Ag |
Compositions and methods to treat cancer
|
|
BR112020001719A2
(pt)
|
2017-07-29 |
2020-07-21 |
Juno Therapeutics Inc |
reagentes para expansão de células que expressam receptores recombinantes
|
|
BR112020001601A2
(pt)
|
2017-08-09 |
2020-08-11 |
Juno Therapeutics Inc |
métodos e composições para preparar células geneticamente manipuladas
|
|
MX2020001490A
(es)
|
2017-08-09 |
2020-08-06 |
Juno Therapeutics Inc |
Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
|
|
EP3679370A1
(en)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
|
CA3079407A1
(en)
|
2017-10-18 |
2019-04-25 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
KR20200069358A
(ko)
|
2017-10-25 |
2020-06-16 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
SG11202003427XA
(en)
|
2017-11-06 |
2020-05-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
WO2019099744A1
(en)
|
2017-11-15 |
2019-05-23 |
Adicet Bio, Inc. |
METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
|
|
KR20200116081A
(ko)
|
2017-12-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포의 투약 및 조절 방법
|
|
EP3720949A1
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
JP2021505615A
(ja)
|
2017-12-08 |
2021-02-18 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法および関連方法のための表現型マーカー
|
|
WO2019113557A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
|
MA51302A
(fr)
*
|
2017-12-21 |
2021-03-31 |
Hoffmann La Roche |
Anticorps se liant à hla-a2/wt1
|
|
EP3729080B1
(en)
|
2017-12-21 |
2023-04-19 |
F. Hoffmann-La Roche AG |
Universal reporter cell assay for specificity test of novel antigen binding moieties
|
|
JP7549303B2
(ja)
|
2018-01-22 |
2024-09-11 |
エンドサイト・インコーポレイテッド |
Car t細胞の使用方法
|
|
EP3746117A1
(en)
|
2018-01-31 |
2020-12-09 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
|
CN111936518A
(zh)
|
2018-02-06 |
2020-11-13 |
西雅图儿童医院(Dba西雅图儿童研究所) |
对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
|
|
EP3752601A4
(en)
|
2018-02-15 |
2022-03-23 |
Memorial Sloan-Kettering Cancer Center |
FOXP3-TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY
|
|
CN112105382A
(zh)
|
2018-02-23 |
2020-12-18 |
恩多塞特公司 |
用于car t细胞疗法的顺序方法
|
|
MA52656A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
|
|
WO2019210055A2
(en)
|
2018-04-26 |
2019-10-31 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3788138A1
(en)
|
2018-05-02 |
2021-03-10 |
Novartis AG |
Regulators of human pluripotent stem cells and uses thereof
|
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
CN108676098A
(zh)
*
|
2018-05-29 |
2018-10-19 |
段海峰 |
靶向wt1的嵌合抗原受体t细胞及其应用
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
AU2019311077B2
(en)
|
2018-07-23 |
2025-05-29 |
Heidelberg Pharma Research Gmbh |
Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
|
|
JP7538109B2
(ja)
|
2018-08-09 |
2024-08-21 |
ジュノー セラピューティクス インコーポレイテッド |
組み込まれた核酸を評価するための方法
|
|
CN113474450A
(zh)
|
2018-08-09 |
2021-10-01 |
朱诺治疗学股份有限公司 |
产生工程化细胞的方法以及所述工程化细胞的组合物
|
|
US12366580B2
(en)
|
2018-09-11 |
2025-07-22 |
Juno Therapeutics, Inc. |
Methods for mass spectrometry analysis of engineered cell compositions
|
|
IT201800009282A1
(it)
*
|
2018-10-09 |
2020-04-09 |
Metis Prec Medicine Sb Srl |
Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
|
|
JP7582940B2
(ja)
|
2018-10-31 |
2024-11-13 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞の選択および刺激のための方法ならびにそのための装置
|
|
GB201817821D0
(en)
*
|
2018-10-31 |
2018-12-19 |
Ospedale San Raffaele Srl |
TCR and peptides
|
|
BR112021010354A2
(pt)
|
2018-11-30 |
2021-11-03 |
Juno Therapeutics Inc |
Métodos para o tratamento usando terapia celular adotiva
|
|
CA3126896A1
(en)
|
2018-12-03 |
2020-06-11 |
Adicet Bio Inc. |
Methods for selective in vivo expansion of .gamma. .delta. t-cell populations and compositions thereof
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
3-(1-オキソ-5-(ピペリジン-4-イル)イソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN114007640A
(zh)
|
2019-05-01 |
2022-02-01 |
朱诺治疗学股份有限公司 |
从修饰的cd247基因座表达嵌合受体的细胞、相关多核苷酸和方法
|
|
US20220184131A1
(en)
|
2019-05-01 |
2022-06-16 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
AU2020293230A1
(en)
|
2019-06-12 |
2022-01-27 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
|
|
WO2021013950A1
(en)
|
2019-07-23 |
2021-01-28 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
|
JP2022545467A
(ja)
|
2019-08-22 |
2022-10-27 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法とzesteホモログ2エンハンサー(EZH2)阻害剤との併用療法および関連方法
|
|
WO2021042019A1
(en)
|
2019-08-30 |
2021-03-04 |
Agenus Inc. |
Anti-cd96 antibodies and methods of use thereof
|
|
AR120563A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quimérico cd19 y cd22 y sus usos
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
KR102688094B1
(ko)
*
|
2019-11-29 |
2024-07-25 |
주식회사 대웅제약 |
Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도
|
|
CN115443150A
(zh)
*
|
2019-12-17 |
2022-12-06 |
德克萨斯大学系统董事会 |
新型ddr1抗体和其用途
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
KR20220146480A
(ko)
|
2020-01-28 |
2022-11-01 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 형질도입 방법
|
|
IL295980A
(en)
*
|
2020-02-28 |
2022-10-01 |
Brigham & Womens Hospital Inc |
Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
|
|
KR20230024283A
(ko)
|
2020-05-13 |
2023-02-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
KR20230042283A
(ko)
|
2020-06-26 |
2023-03-28 |
주노 테라퓨틱스 게엠베하 |
재조합 수용체를 조건부로 발현하는 조작된 t 세포, 관련된 폴리뉴클레오티드 및 방법
|
|
EP4188395A1
(en)
|
2020-07-30 |
2023-06-07 |
Institut Curie |
Immune cells defective for socs1
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
WO2022144025A1
(zh)
*
|
2021-01-04 |
2022-07-07 |
上海翰森生物医药科技有限公司 |
一种抗erbb3受体的抗体或其抗原结合片段及其医药用途
|
|
US12447218B1
(en)
*
|
2021-02-09 |
2025-10-21 |
Actinium Pharmaceuticals, Inc. |
Radioconjugates directed to MHC-complexed antigens in cancer
|
|
AU2022244229A1
(en)
|
2021-03-22 |
2023-09-14 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
|
JP2024514245A
(ja)
|
2021-03-29 |
2024-03-29 |
ジュノー セラピューティクス インコーポレイテッド |
チェックポイント阻害剤療法とcar t細胞療法との組合せを用いた投薬および処置のための方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
EP4330381A1
(en)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
Viral vector production system
|
|
US20240269282A1
(en)
|
2021-05-10 |
2024-08-15 |
Institut Curie |
Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
|
|
US20250304915A1
(en)
|
2021-05-25 |
2025-10-02 |
Institut Curie |
Myeloid Cells Overexpressing BCL2
|
|
EP4456910A1
(en)
|
2021-12-28 |
2024-11-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
|
CN120077132A
(zh)
|
2022-01-21 |
2025-05-30 |
姆内莫治疗公司 |
Rna对suv39h1表达的调控
|
|
JP2025504002A
(ja)
|
2022-01-28 |
2025-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
細胞組成物を製造する方法
|
|
CN114539412B
(zh)
*
|
2022-02-24 |
2023-09-29 |
广西医科大学 |
抗hla-a2/wt1复合物的单域抗体及其制备方法与应用
|
|
EP4499677A1
(en)
|
2022-03-31 |
2025-02-05 |
Institut Curie |
Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024088383A1
(en)
*
|
2022-10-28 |
2024-05-02 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Anti-wt1/hla antibodies and uses thereof
|
|
AU2024217436A1
(en)
*
|
2023-02-06 |
2025-08-14 |
Eureka Therapeutics, Inc. |
Compositions including anti-wt-1 antibodies antigen binding fragments and uses thereof
|
|
KR20250169631A
(ko)
|
2023-04-18 |
2025-12-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2025163107A1
(en)
|
2024-02-01 |
2025-08-07 |
Institut Gustave Roussy |
Immune cells defective for znf217 and uses thereof
|